코센틱스(COSENTYX) 판매 예측 및 시장 규모 분석(2034년)

Key Factors Driving COSENTYX Growth

1. Blockbuster biologic with sustained high revenue base

• COSENTYX generated ~USD 4.98 billion in 2023 sales, confirming blockbuster status.
• Quarterly sales have consistently exceeded USD 1.3-1.6 billion, reflecting strong global demand.

Impact:

• A large installed patient base provides recurring revenue and durable growth, forming a strong foundation for continued expansion.

2. Strong double-digit growth momentum across recent years

• COSENTYX recorded ~21% growth in 2023 (Q4 YoY) and ~25% growth contribution in 2024 performance drivers.
• Continued growth of +8-11% in 2025-2026 indicates sustained momentum even at scale.
• Q3 2024 growth reached ~28% (cc), highlighting strong uptake acceleration.

Impact:

• Demonstrates consistent expansion across geographies and indications, not just maturity-phase stabilization.

3. Broad and expanding label across multiple inflammatory diseases

• COSENTYX is approved for:
• Plaque psoriasis
• Psoriatic arthritis (PsA)
• Ankylosing spondylitis (AS)
• Non-radiographic axial spondyloarthritis
• Hidradenitis suppurativa (recent addition)

Impact:

• Multi-indication use significantly expands the addressable patient population, enabling cross-specialty adoption (dermatology + rheumatology).

4. First-in-class IL-17A inhibitor with strong efficacy profile

• COSENTYX is a fully human monoclonal antibody targeting IL-17A, a key cytokine in inflammatory pathways.
• Clinical trials have shown high PASI90/100 response rates in psoriasis, superior or competitive vs TNF inhibitors (published literature/PUBMED evidence).

5. Continuous lifecycle management and formulation innovation

• Novartis has expanded COSENTYX via:
• Intravenous (IV) formulation approvals (2023)
• New indications and earlier-line positioning
• Ongoing studies aim to extend into additional inflammatory conditions

COSENTYX Recent Developments

• In September 2025, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 2025, offering cash-paying patients prescribed COSENTYX (secukinumab) the option to purchase it at a 55% discount off the list price. COSENTYX, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis. It has been studied clinically for more than 17 years and has been used to treat more than 1.8 million patients globally since its launch in 2015.

"COSENTYX Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of COSENTYX for approved indication like Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus in the 7MM. A detailed picture of COSENTYX's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the COSENTYX for approved and potential indications. The COSENTYX market report provides insights about COSENTYX's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current COSENTYX performance, future market assessments inclusive of the COSENTYX market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of COSENTYX sales forecasts, along with factors driving its market.

COSENTYX Drug Summary

COSENTYX is a fully human IgG1κ monoclonal antibody developed by Novartis, FDA-approved for multiple autoimmune inflammatory conditions including moderate-to-severe plaque psoriasis in adults and children aged 6 years and older, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis in patients 4 years and older, and moderate-to-severe hidradenitis suppurativa in adults. It selectively binds to and neutralizes interleukin-17A (IL-17A), a key proinflammatory cytokine driving inflammation, thereby reducing immune overactivity that causes skin plaques, joint damage, and other symptoms in these diseases. Administered subcutaneously via pre-filled Sensoready pen, autoinjector, or syringe at a loading dose (300 mg weekly for 5 weeks) followed by 300 mg monthly (or 150 mg/75 mg for lower weight/body surface area adjustments), it features common side effects like upper respiratory infections, diarrhea, and increased risk of infections, with contraindications for active tuberculosis or hypersensitivity. The report provides COSENTYX's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the COSENTYX Market Report

The report provides insights into:

• A comprehensive product overview including the COSENTYX MoA, description, dosage and administration, research and development activities in approved indications like Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus.
• Elaborated details on COSENTYX regulatory milestones and other development activities have been provided in COSENTYX market report.
• The report also highlights COSENTYX's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The COSENTYX market report also covers the patents information, generic entry and impact on cost cut.
• The COSENTYX market report contains current and forecasted COSENTYX sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The COSENTYX market report also features the SWOT analysis with analyst views for COSENTYX in approved and potential indications.

Methodology:

The COSENTYX market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

COSENTYX Analytical Perspective by DelveInsight

• In-depth COSENTYX Market Assessment

This COSENTYX sales market forecast report provides a detailed market assessment of COSENTYX for approved indication like Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted COSENTYX sales data uptil 2034.

• COSENTYX Clinical Assessment

The COSENTYX market report provides the clinical trials information of COSENTYX for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

COSENTYX Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

COSENTYX Market Potential & Revenue Forecast

• Projected market size for the COSENTYX and its key indications
• Estimated COSENTYX sales potential (COSENTYX peak sales forecasts)
• COSENTYX Pricing strategies and reimbursement landscape

COSENTYX Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• COSENTYX Market positioning compared to existing treatments
• COSENTYX Strengths & weaknesses relative to competitors

COSENTYX Regulatory & Commercial Milestones

• COSENTYX Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

COSENTYX Clinical Differentiation

• COSENTYX Efficacy & safety advantages over existing drugs
• COSENTYX Unique selling points

COSENTYX Market Report Highlights

• In the coming years, the COSENTYX market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The COSENTYX companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence COSENTYX's dominance.
• Other emerging products for Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus are expected to give tough market competition to COSENTYX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of COSENTYX in approved and potential indications.
• Analyse COSENTYX cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted COSENTYX sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of COSENTYX in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of COSENTYX? How strong is COSENTYX's clinical and commercial performance?
• What is COSENTYX's clinical trial status in each individual indications such as Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the COSENTYX Manufacturers?
• What are the key designations that have been granted to COSENTYX for approved and potential indications? How are they going to impact COSENTYX's penetration in various geographies?
• What is the current and forecasted COSENTYX market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of COSENTYX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to COSENTYX for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is COSENTYX? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. COSENTYX Overview in approved indications like Ankylosing spondylitis, Hidradenitis suppurativa, Non-radiographic axial spondyloarthritis, Plaque psoriasi; as well as potential indication like Graves ophthalmopathy, Polymyalgia rheumatica, Atopic dermatitis, and Discoid lupus erythematosus

• 2.1. Product Detail
• 2.2. COSENTYX Clinical Development
  • 2.2.1. COSENTYX Clinical studies
  • 2.2.2. COSENTYX Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. COSENTYX Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging COSENTYX Therapies)

5. COSENTYX Market Assessment

• 5.1. COSENTYX Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. COSENTYX Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. COSENTYX Market Size in the United States for approved and potential indications
  • 5.3.2. COSENTYX Market Size in Germany for approved and potential indications
  • 5.3.3. COSENTYX Market Size in France for approved and potential indications
  • 5.3.4. COSENTYX Market Size in Italy for approved and potential indications
  • 5.3.5. COSENTYX Market Size in Spain for approved and potential indications
  • 5.3.6. COSENTYX Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. COSENTYX Market Size in Japan for approved and potential indications

6. COSENTYX SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options